Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00125463
Status:
UNKNOWN
Last Update Posted:
2005-08-10
First Post:
2005-07-29
Brief Title:
Candesartan Antihypertensive Survival Evaluation in Japan CASE-J Trial of Cardiovascular Events in High-Risk Hypertensive Patients
Sponsor:
The Japanese Society of Hypertension
Organization:
The Japanese Society of Hypertension
Study Overview
Official Title:
Candesartan Antihypertensive Survival Evaluation in Japan CASE-J Trial of Cardiovascular Events in High-Risk Hypertensive Patients
Status:
UNKNOWN
Status Verified Date:
2005-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare an angiotensin II receptor antagonist candesartan cilexetil- Blopress and a calcium channel blocker amlodipine besilate- NorvascAmlodin in terms of the incidence of cardiovascular events among high-risk hypertensive patients
Detailed Description:
Hypertension continues to be a major public health issue in the world To combat this problem many antihypertensive drugs have been developed and proven effective at controlling blood pressure in the last half century In recent decades antihypertensive drugs have been shown to have cardiovascular benefits beyond the reduction of blood pressure and the focus has shifted to clarification of these effects Angiotensin II receptor antagonists and calcium channel blockers are the most widely used antihypertensive drugs in Japan However these two classes of drugs have not yet been compared with respect to their efficacy for treating cardiovascular events
Comparison Response-dependent dose titration and blinded assessment of endpoints in high risk hypertensive patients treated with either an angiotensin II receptor antagonist candesartan cilexetil compared to a third-generation calcium channel blocker amlodipine besilate
Comparison Response-dependent dose titration and blinded assessment of endpoints in high risk hypertensive patients treated with either an angiotensin II receptor antagonist candesartan cilexetil compared to a third-generation calcium channel blocker amlodipine besilate
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None